Dimensional Fund Advisors LP Boosts Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Dimensional Fund Advisors LP lifted its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 154.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,966 shares of the company’s stock after buying an additional 16,954 shares during the period. Dimensional Fund Advisors LP’s holdings in ImmunityBio were worth $72,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of ImmunityBio by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 17,328,229 shares of the company’s stock worth $44,360,000 after acquiring an additional 425,713 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in ImmunityBio by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,276,673 shares of the company’s stock valued at $3,268,000 after purchasing an additional 10,692 shares during the period. Altium Capital Management LLC purchased a new stake in ImmunityBio during the fourth quarter worth approximately $2,714,000. Clearwater Capital Advisors LLC grew its stake in ImmunityBio by 75.4% during the fourth quarter. Clearwater Capital Advisors LLC now owns 846,419 shares of the company’s stock worth $2,167,000 after buying an additional 363,870 shares during the period. Finally, Barclays PLC lifted its position in shares of ImmunityBio by 9.8% during the fourth quarter. Barclays PLC now owns 396,484 shares of the company’s stock worth $1,015,000 after purchasing an additional 35,448 shares in the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Trading Up 6.4%

NASDAQ IBRX opened at $2.84 on Monday. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $7.64. The stock’s 50-day moving average price is $2.64 and its two-hundred day moving average price is $3.27. The company has a market cap of $2.51 billion, a PE ratio of -3.09 and a beta of 0.33.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The firm had revenue of $16.52 million for the quarter, compared to analyst estimates of $17.50 million. Research analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on IBRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a report on Monday, May 12th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Monday, May 12th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.